Verapamil delivery systems on the basis of mesoporous ZSM-5/KIT-6 and ZSM-5/SBA-15 polymer nanocomposites as a potential tool to overcome MDR in cancer cells.
Antineoplastic Agents
/ chemistry
Cell Line, Tumor
Chitosan
/ chemistry
Doxorubicin
/ chemistry
Drug Carriers
/ chemistry
Drug Compounding
/ methods
Drug Delivery Systems
/ methods
Drug Resistance, Multiple
/ drug effects
HL-60 Cells
HT29 Cells
Humans
Hydrogen-Ion Concentration
Nanocomposites
/ chemistry
Nanoparticles
/ chemistry
Polymers
/ chemistry
Porosity
Silicon Dioxide
/ chemistry
Verapamil
/ chemistry
Delivery systems
Multi-drug resistance
Surface modification
Verapamil
Zeolite/mesoporous silica nanocomposites
Journal
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778
Informations de publication
Date de publication:
Sep 2019
Sep 2019
Historique:
received:
17
02
2019
revised:
10
07
2019
accepted:
19
07
2019
pubmed:
25
7
2019
medline:
26
11
2019
entrez:
24
7
2019
Statut:
ppublish
Résumé
ZSM-5/KIT-6 and ZSM-5/SBA-15 nanoparticles were synthesized and further modified by a post-synthesis method with (CH
Identifiants
pubmed: 31336182
pii: S0939-6411(19)30194-8
doi: 10.1016/j.ejpb.2019.07.021
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Drug Carriers
0
Polymers
0
SBA-15
0
Silicon Dioxide
7631-86-9
Doxorubicin
80168379AG
Chitosan
9012-76-4
Verapamil
CJ0O37KU29
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
460-472Informations de copyright
Copyright © 2019 Elsevier B.V. All rights reserved.